Precision therapy for three Chinese families with maturity-onset diabetes of the young (MODY12)
- PMID: 35992135
- PMCID: PMC9381955
- DOI: 10.3389/fendo.2022.858096
Precision therapy for three Chinese families with maturity-onset diabetes of the young (MODY12)
Abstract
Maturity-onset diabetes of the young (MODY) is rare monogenic diabetes. However, MODY is often undiagnosed or misdiagnosed. In this study, we aimed to investigate the pathogenic gene for diabetes and provide precise treatment for diabetes patients in three families. Three families with suspected MODY were enrolled and screened for germline mutations using Whole exome sequencing (WES). Candidate pathogenic variants were validated in other family members and non-related healthy controls. Three heterozygous missense mutations in the ABCC8 gene (NM_001287174), c.1555 C>T (p.R519C), c.3706 A>G (p.I1236V), and c.2885 C>T (p.S962L) were found in families A, B, and C, respectively. All mutation sites cosegregated with diabetes, were predicted to be harmful by bioinformatics and were not found in non-related healthy controls. Two probands (onset ages, 8 and 12 years) were sensitive to glimepiride. However, an insufficient dose (2 mg/day) led to ketoacidosis. When the dosage of glimepiride was increased to 4 mg/day, blood sugar remained under control. A dose of 4 mg glimepiride daily also effectively controlled blood sugar in an adult patient 25-year-old. In addition, all patients were sensitive to liraglutide, which could control blood sugar better. These data suggest that ABCC8 was the pathogenic gene in three families with diabetes. Glimepiride (2 mg/day) was not effective in controlling blood sugar in children with ABCC8 mutations, however, 4 mg/daily glimepiride was effective in both adults and children. Moreover, liraglutide was effective in controlling blood sugar in both adults and children with ABCC8 mutations.
Keywords: ABCC8; MODY12; mutation; precision therapy; whole exome sequencing.
Copyright © 2022 Li, Wang, Mao, Wen, Deng, Li, Zhang and Liu.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures


Similar articles
-
Identification of heterozygous mutations of ABCC8 gene responsible for maturity-onset diabetes of the young with exome sequencing.Acta Diabetol. 2025 Jun;62(6):935-942. doi: 10.1007/s00592-024-02410-1. Epub 2024 Nov 18. Acta Diabetol. 2025. PMID: 39556225 Free PMC article.
-
A case report of maturity-onset diabetes of the young (MODY12) in a Chinese Han patient with a novel ABCC8 gene mutation.Medicine (Baltimore). 2022 Dec 9;101(49):e32139. doi: 10.1097/MD.0000000000032139. Medicine (Baltimore). 2022. PMID: 36626423 Free PMC article.
-
ABCC8-Related Maturity-Onset Diabetes of the Young (MODY12): A Report of a Chinese Family.Front Endocrinol (Lausanne). 2020 Sep 11;11:645. doi: 10.3389/fendo.2020.00645. eCollection 2020. Front Endocrinol (Lausanne). 2020. PMID: 33013711 Free PMC article.
-
Clinical features, complications and treatment of rarer forms of maturity-onset diabetes of the young (MODY) - A review.J Diabetes Complications. 2021 Jan;35(1):107640. doi: 10.1016/j.jdiacomp.2020.107640. Epub 2020 May 29. J Diabetes Complications. 2021. PMID: 32763092 Review.
-
Primary hepatocellular adenoma due to biallelic HNF1A mutations and its co-occurrence with MODY 3: case-report and review of the literature.Endocrine. 2020 Mar;67(3):544-551. doi: 10.1007/s12020-019-02138-x. Epub 2019 Nov 21. Endocrine. 2020. PMID: 31754975 Free PMC article. Review.
Cited by
-
Identification and precision therapy for three maturity-onset diabetes of the young (MODY) families caused by mutations in the HNF4A gene.Front Endocrinol (Lausanne). 2023 Aug 29;14:1237553. doi: 10.3389/fendo.2023.1237553. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37711893 Free PMC article.
-
Identification of heterozygous mutations of ABCC8 gene responsible for maturity-onset diabetes of the young with exome sequencing.Acta Diabetol. 2025 Jun;62(6):935-942. doi: 10.1007/s00592-024-02410-1. Epub 2024 Nov 18. Acta Diabetol. 2025. PMID: 39556225 Free PMC article.
-
Adipose-Derived Stem Cell Exosomes Facilitate Diabetic Wound Healing: Mechanisms and Potential Applications.Int J Nanomedicine. 2024 Jun 17;19:6015-6033. doi: 10.2147/IJN.S466034. eCollection 2024. Int J Nanomedicine. 2024. PMID: 38911504 Free PMC article. Review.
-
Genetic and clinical insights into acute kidney injury in maturity-onset diabetes of the young caused by the ABCC8 c.2500C>T mutation: Potential risk factors associated with SGLT2 inhibitors.Exp Ther Med. 2025 Jun 26;30(2):164. doi: 10.3892/etm.2025.12914. eCollection 2025 Aug. Exp Ther Med. 2025. PMID: 40630230 Free PMC article.
-
Stem Cell-Derived Extracellular Vesicles: Promising Therapeutic Opportunities for Diabetic Wound Healing.Int J Nanomedicine. 2024 May 17;19:4357-4375. doi: 10.2147/IJN.S461342. eCollection 2024. Int J Nanomedicine. 2024. PMID: 38774027 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical